Profound Medical Corp. is a commercial-stage medical device company focused on magnetic resonance guided ablation procedures for prostate disease treatment. The company boasts a strong gross margin of 78.4%, indicating effective cost management, but faces significant concerns with negative EBITDA and net margins, reflecting ongoing operational losses. Additionally, its high current and quick ratios suggest excellent liquidity, yet the low debt/equity ratio indicates minimal leverage, which could limit growth potential. Overall, while the company has solid margins, its financial health raises questions about sustainability and profitability.
Loading financial metrics...
Company posted a loss of $-32.7M over the last year, representing 171.6% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $36.1M over the last year.
Exceptional revenue growth of 67.9% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 190.4pp, demonstrating strong operational leverage.
Both gross margin (+3.2pp) and operating margin (+190.4pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 71.8% indicates strong pricing power and competitive moat.
Gross margin improvement of 3.2pp suggests operational efficiency gains.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical - Devices companies of a similar size
Based on 2026-Q2 (June 30, 2026)